Essential Thrombocythemia

Common Name(s)

Essential Thrombocythemia

Essential thrombocythemia belongs to a group of conditions called myeloproliferative disorders. Myeloproliferative disorders cause platelets, white blood cells and red blood cells to grow abnormally in the bone marrow (the soft tissue inside the hollow part of bones that helps form blood cells). In essential thrombocythemia, the body produces too many platelet cells. The signs and symptoms vary from person to person, with up to two-thirds of patients not having any symptoms when the platelet cell count first increases. Signs and symptoms may include significant increased production of megakaryocyte (a cell in the bone marrow that is responsible for making platelets), enlargement of the spleen (splenomegaly), and bleeding and/or clotting episodes.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Essential Thrombocythemia" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Essential Thrombocythemia" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

http://www.mpnresearchfoundation.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Essential Thrombocythemia" returned 240 free, full-text research articles on human participants. First 3 results:

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
 

Author(s): Ayalew Tefferi, Paola Guglielmelli, Dirk R Larson, Christy Finke, Emnet A Wassie, Lisa Pieri, Naseema Gangat, Rajmonda Fjerza, Alem A Belachew, Terra L Lasho, Rhett P Ketterling, Curtis A Hanson, Alessandro Rambaldi, Guido Finazzi, Juergen Thiele, Tiziano Barbui, Animesh Pardanani, Alessandro M Vannucchi

Journal: Blood. 2014 Oct;124(16):2507-13; quiz 2615.

 

Janus kinase 2 (JAK2) mutations define polycythemia vera (PV). Calreticulin (CALR) and myeloproliferative leukemia virus oncogene (MPL) mutations are specific to JAK2-unmutated essential thrombocythemia (ET) and primary myelofibrosis (PMF). We examined the effect of these mutations ...

Last Updated: 17 Oct 2014

Go To URL
Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients.
 

Author(s): Chun Qiao, Chao Sun, Yuan Ouyang, Ju-Juan Wang, Si-Xuan Qian, Jian-Yong Li, Su-Jiang Zhang

Journal: Haematologica. 2014 Oct;99(10):e182-4.

 

Last Updated: 1 Oct 2014

Go To URL
Interferon alfa therapy in CALR-mutated essential thrombocythemia.
 

Author(s): Bruno Cassinat, Emmanuelle Verger, Jean-Jacques Kiladjian

Journal: N. Engl. J. Med.. 2014 Jul;371(2):188-9.

 

Last Updated: 10 Jul 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Essential Thrombocythemia" returned 11 free, full-text review articles on human participants. First 3 results:

[Coexistence of multiple myeloma with essential thrombocythemia: a case report and literatures review].
 

Author(s): Jing Huang, Xiaohua Luo, Yan Zhu, Li Wang, Lin Liu

Journal: Zhonghua Xue Ye Xue Za Zhi. 2014 Aug;35(8):757-9.

 

Last Updated: 25 Aug 2014

Go To URL
Personalized management of essential thrombocythemia-application of recent evidence to clinical practice.
 

Author(s): A Tefferi, T Barbui

Journal: Leukemia. 2013 Aug;27(8):1617-20.

 

The World Health Organization (WHO) classification system has recently strengthened the diagnostic criteria for essential thrombocythemia (ET) by lowering the threshold platelet count, underscoring its morphological distinction from early/prefibrotic myelofibrosis (MF) and incorporating ...

Last Updated: 7 Aug 2013

Go To URL
Management of essential thrombocythemia.
 

Author(s): Francisco Cervantes

Journal: Hematology Am Soc Hematol Educ Program. 2011 ;2011():215-21.

 

Essential thrombocythemia (ET) is a Philadelphia chromosome (Ph)-negative myeloproliferative neoplasm (MPN) characterized by thrombocytosis and megakaryocytic hyperplasia of the bone marrow, with presence of the JAK2 V617F mutation in 50%-60% of patients. ET evolves to myelofibrosis ...

Last Updated: 14 Dec 2011

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis
 

Status: Available

Condition Summary: Myelofibrosis (PMF); Post Polycythemia Myelofibrosis (PPV MF); Post-essential Thrombocythemia Myelofibrosis (PET-MF); Myelofibrosis; Post Polycythemia Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

 

Last Updated: 7 Apr 2015

Go to URL
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
 

Status: Recruiting

Condition Summary: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia

 

Last Updated: 5 Mar 2015

Go to URL
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
 

Status: Recruiting

Condition Summary: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia

 

Last Updated: 5 Mar 2015

Go to URL